Company: ARWR
Filing Date: 2025-01-29
Form Type: ARS
Source: 0001628280-25-002866
Chunk: 206

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-01-29
Form: ARS
Chunk 206
---
496 15,761 3,512,376 Chief Financial Officer 2023 568,128 — 2,284,800 252,000 14,215 3,119,143 2022 509,648 — 3,978,000 238,106 13,798 4,739,552 Patrick O’Brien 2024 605,259 — 2,935,050 378,000 15,261 3,933,570 Chief Operating Officer and General Counsel 2023 568,422 — 2,475,200 252,000 14,715 3,310,337 2022 500,466 — 3,978,000 235,599 13,798 4,727,863 James Hamilton 2024 567,937 — 2,589,750 314,496 15,261 3,487,444 Chief of Discovery and Translational Medicine 2023 511,178 — 2,284,800 236,250 14,715 3,046,943 2022 450,436 — 3,646,500 212,580 13,798 4,323,314 Javier San Martin (8) 2024 260,529 — 2,589,750 — 606,285 3,456,564 Former Chief Medical Officer 2023 544,467 — 2,284,800 252,000 14,715 3,095,982 2022 479,170 — — 225,574 — 704,744 Tracie Oliver (8) 2024 484,065 — 2,589,750 — 2,965 3,076,780 Former Chief Commercial Officer 2023 647,261 — 19,040 188,000 19,521 873,822 2022 111,154 16,344 2,517,200 94,874 4,899 2,744,471 (1) This column represents the total grant date fair value, computed in accordance with ASC 718, of RSUs granted during fiscal years 2024, 2023 and 2022. The assumptions used to calculate the value of the stock underlying the RSU awards are set forth in Note 9 of the Notes to the Consolidated Financial Statements included with the Company’s Annual Report on Form 10-K.